Prediction of resistance to intravenous immunoglobulin in children with Kawasaki disease

Journal of the Pediatric Infectious Diseases Society

Volumn 7, Issue 1, 2018, Pages 25-29

  Bar Meir, Maskit ^a,b   Kalisky, Itai ^a   Schwartz, Andrei ^c   Somekh, Eli ^c,d   Tasher, Diana ^c,d   Ashkenazi, Shai ^d   Averbuch, Diana ^d   Miron, Dan ^d   Guri, Alex ^d   Stein, Michal ^d   Greenberg, David ^d   Glikman, Daniel ^d   Efrat, Moshe ^d   Chaim, Barak ^d   Youngster, Ilan ^d   Barzilai, Asher ^d   Srugo, Itzhak ^d   Shachor Meyouhas, Yael ^d  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c WOLFSON MEDICAL CENTER   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

Coronary arteries; Glucocorticoids; Sensitivity; Specificity

Indexed keywords

IMMUNOGLOBULIN;

ARTICLE; CHILD; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ECHOCARDIOGRAPHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; OUTCOME ASSESSMENT; PREDICTION; PRESCHOOL CHILD; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; ADOLESCENT; AGE; INFANT; NEWBORN; RISK FACTOR; SEX FACTOR; TREATMENT FAILURE; TREATMENT OUTCOME;

ADOLESCENT; AGE FACTORS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFANT; INFANT, NEWBORN; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 85018194223     PISSN: 20487193     EISSN: 20487207     Source Type: Journal    
DOI: 10.1093/jpids/piw075     Document Type: Article

References (15)

1. Newburger JW, Fulton DR. Kawasaki disease. Curr Treat Options Cardiovasc Med 2007; 9:148-58.
2. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and longterm management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2004; 110:2747-71.
3. Kobayashi T, Saji T, Otani T, et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet 2012; 379:1613-20.
4. Tremoulet AH, Jain S, Jaggi P, et al. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet 2014; 383:1731-8.
5. Reindel R, Shulman ST. Paediatric rheumatology: corticosteroids as primary therapy in Kawasaki disease. Nat Rev Rheumatol 2012; 8:373-4.
6. Kobayashi T, Inoue Y, Takeuchi K, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 2006; 113:2606-12.
7. Sano T, Kurotobi S, Matsuzaki K, et al. Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. Eur J Pediatr 2007; 166:131-7.
8. Egami K, Muta H, Ishii M, et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr 2006; 149:237-40.
9. Sleeper LA, Minich LL, McCrindle BM, et al. Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance. J Pediatr 2011; 158:831-835.e3.
10. Tremoulet AH, Best BM, Song S, et al. Resistance to intravenous immunoglobulin in children with Kawasaki disease. J Pediatr 2008; 153:117-21.
11. Bar-Meir M, Haklai Z, Dor M. Kawasaki disease in Israel. Pediatr Infect Dis J 2011; 30:589-92.
12. Dominguez SR, Anderson MS, El-Adawy M, Glodé MP. Preventing coronary artery abnormalities: a need for earlier diagnosis and treatment of Kawasaki disease. Pediatr Infect Dis J 2012; 31:1217-20.
13. Sleeper LA, Minich LL, McCrindle BM, et al. Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance. J Pediatr 2011; 158:831-835.e3.
14. Newburger JW, Sleeper LA, McCrindle BW, et al. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med 2007; 356:663-75.
15. McGinn TG, Guyatt GH, Wyer PC, et al. Users' guides to the medical literature: XXII: how to use articles about clinical decision rules. Evidence-based medicine working group. JAMA 2000; 284:79-84.